U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 09/890,088 INFORMATION DISCLOSURE Filing Date 07-26-01 STATEMENT BY APPLICANT First Named Inventor Alessandro Lambiase Art Unit 1647 (Use as many sheets as necessary) Examiner Name C. Woodward Sheet 1 of 2 Attorney Docket Number 5979-0107PUS1

			U.S. PATE	NT DOCUMENTS	
Examiner Cité No.	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear
	NO.	Number - Kind Code 2 (if known)			
	1	US-2002/0009498 - A1	01-24-2002	Clifton, et al.	
	2	US-2003/0181354 - A1	09-25-2003	Abdulrazik	
	3	US-4,959,319 - A	09-25-1990	Skelnik et al.	
	4	US-5,641,479 - A	06-24-1997	Linares et al.	
	5	US-6,056,950 - A	05-02-2000	Saettone et al.	

	Cite	Foreign Patent Document			Pages, columns, Lines, Where Relevant Passages or Relevent Figures Appear
	No. 1	Country ³ Number ⁴ Kind Code (if known) ⁵	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
	6	WO 00/07613 - A1	02-17-2000	Advanced Medicine Research Ir	
	7	WO 00/44396 - A1	08-03-2000	Anabasis SRL	
	8	EP 0572364 - A2	12-01-1993	Istituto Nazionale Per La Rice	
	9	DE 3827477 - A1	02-22-1990	Biotechnolog Forschung	
	10	WO 92/15614 - A1	09-17-1992	Chiron Ophthalmics, Inc.	

-		
Examiner Signature	Date Considered	

EXAMINER: Initial If inference considered, whether or not dation is in conformance with MEPS 050. Done ison through classics in fool is conformance and not Considered. Fooliage over on the fooliage is communication to applicant. A applicant is ruigh, each allow disapple manter (procinal), 28 eef Mino Codor of USPTO patent Documents at www.scripo.govo MEPS 010.13. Either Diffice hat issued the document, by the involvance patent of the patent document of the patent document of the patent document. As find and one of the patent document of the patent document under WIPO Standard ST. 18 if possible 6. Applicant is to place a check mark hore if English language.

This collection of information is required by 3T CRR 137 and 1.88. The information is required to obtain or retain a benefit by the public which is to fit (only by the USPTO in process) an application. Confidentially is powered by 51 US. CL 22 and 32 CRR 114. The positionis is estimated to bias Even to complete, including application, properties, and submitting the completed application form the USPTO. There will vary depending upon the including adjustment of the confidence of the USPTO. There will vary depending upon the included case, they only confidence of the CRR 114 CR

Approved for use through 07/31/2012. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Und	der the Paperwork reduc	tion Act	of 1995, no persons are re	quired to respond to a collection of info	ormation unless it contains a valid OMB control number.	
substitute fo	r form 1449B/PTO			Co	omplete if Known	
INFO	MATION D	ieci	OSLIDE	Application Number	09/890,088	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	07-26-01	
				First Named Inventor	Alessandro Lambiase	
				Art Unit	1647	
				Examiner Name	C. Woodward	
Choot	2	of	2	Attorney Docket Number	5070-0107DLIS1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), uolume-issue number(s), publisher, city and/or country where published.	T 2
	11	EPO International Search Report, Appl. No. PCT/IT2006/000620, February 9, 2007	F
	12	JACKOWSKI, A., "Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer," British Journal of Neurosurgery, 1995, vol. 9, pp. 303-317	L
	13	LAMBIASE, A. et al., "Increased Plasma Levels of Nerve Growth Factor in Vernal Keratoconjunctivitis and Relationship to Conjunctival Mast Cells," Invest Ophthalmol Vis Sci., Chemical Abstracts, September 1995, vol. 136, no. 10, pp. 2127-2132	E
	14	LAMBIASE, A. et al, "Nerve growth factor delays retinal degeneration in C3H mice," Graefe's Arch Clin Exp Ophthalmol, Chemical Abstracts, November 4, 1996, vol. 25, no. 19	L
	15	Response to March 12, 2004 Office Action, which issued in European Application No. 0090133.9-2107	E
	16	USPTO Office Action, Appl. No. 12/064,172, June 13, 2011	L

Examiner Signature		Date Considered	4			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not						

considered. Include copy of this form with next communication to applicant.

P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{1.} Applicants unique citation designation number (optional) 2. Applicant is to plose a check man here if English Integrated Transplace Translation is attached. This collection of information is required by 27 ET 8 / 29 and 15 in the information is required by 27 in the optional property of cooling or retain a needle by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 55 U.S. of 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, most under a public property of the collection of t